Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

GlobeNewswire November 28, 2022

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

GlobeNewswire November 21, 2022

Arcutis' ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

GlobeNewswire November 17, 2022

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

GlobeNewswire November 15, 2022

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

GlobeNewswire November 15, 2022

Arcutis to Present at Upcoming Investor Conference

GlobeNewswire November 11, 2022

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 8, 2022

Arcutis to Report Third Quarter Financial Results

GlobeNewswire October 25, 2022

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

GlobeNewswire October 21, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 5, 2022

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

GlobeNewswire September 26, 2022

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

GlobeNewswire September 20, 2022

New Data from Arcutis' STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire September 9, 2022

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

PR Newswire September 8, 2022

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

GlobeNewswire September 7, 2022

New Data from Arcutis' Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire September 6, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2022

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

GlobeNewswire September 2, 2022

Arcutis to Present at Upcoming Investor Conference

GlobeNewswire September 1, 2022

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

PR Newswire August 30, 2022